Intravitreal triamcinolone acetonide and central serous chorioretinopathy

Intravitreal bevacizumab in central serous chorioretinopathy.

OBJECTIVE To evaluate the effect of intravitreal bevacizumab injection in patients with central serous chorioretinopathy (CSCR). STUDY DESIGN Quasi-experimental study. PLACE AND DURATION OF STUDY Layton Rehmatullah Benevolent Trust Eye and Cancer Hospital, Lahore, from July 2010 to April 2011. METHODOLOGY There were 43 eyes of 32 adult patients with CSCR. Patients with choroidal neovascul...

Intravitreal Injection of Triamcinolone Acetonide

The introduction of pars plana vitrectomy in clinical ophthalmology by Robert Machemer and colleagues was a profound paradigm change which opened up new avenues for the treatment of ocular diseases, such as proliferative vitreoretinopathy, which up to that time had been incurable [79]. It was again Robert Machemer who together with Yasuo Tano, Gholam Peyman, Stephan Ryan and other researchers f...

Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy

PURPOSE To report the anatomic and functional outcome of intravitreal dobesilate to treat recurrent central serous chorioretinopathy (CSC). METHODS This is an interventional case report in which dobesilate was intravitreally injected in a case of recurrent CSC. Main measures included fundoscopy, Snellen visual acuity (VA) testing, fluorescein angiography and optical coherence tomography (OCT)...

Intravitreal Avastin in the Treatment of Central Serous Chorioretinopathy

Patients treated with intravitreal triamcinolone acetonide

Correspondence: Pier Enrico Gallenga University Eye Clinic, G.D’Annunzio University, Chieti, Italy Email [email protected] Patients treated with intravitreal triamcinolone acetonide The paper by Kocabora and coworkers (2008) underlines the message that patients treated with intravitreal triamcinolone acetonide are at risk of increased intraocular pressure (IOP) even after the clearance period o...